NEW YORK (GenomeWeb News) – A consortium of European companies and universities has been awarded €3 million ($3.8 million) under the European Commission's 7th Framework Program to develop a plasma biomarker discovery platform.
The three-year project, called Proactive, will be coordinated by Olink Bioscience of Uppsala, Sweden. Other partners include Innova Biosciences, Copenhagen University, Fujirebio Diagnostics, Uppsala University, and Integromics.
The goal of the initiative is to develop methods and reagents for multiplexed proximity ligation assays for detecting low-abundance proteins in plasma, along with statistical methods and data-management tools. The participants plan to carry out a series of pilot biomarker projects focused on colorectal cancer detection in blood samples.
The participants plan to develop a platform that can analyze 100 samples per week. The platform will be able to detect 180 putative protein biomarkers using four microliters of plasma, the participants said.
Further information about the project is available here.